Clinical and Fundamental Research Progressions on Tumor-Infiltrating Lymphocytes Therapy in Cancer
Malignant tumors represent a significant threat to human health. Among the various therapeutic strategies available, cancer immunotherapy—encompassing adoptive cell transfer (ACT) and immune checkpoint blockade therapy—has emerged as a particularly promising approach following surgical resection, ra...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-05-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/13/5/521 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849327218381029376 |
|---|---|
| author | Jiandong Hu Mengli Jin Weihong Feng Barbara Nassif-Rausseo Alexandre Reuben Chunhua Ma Gregory Lizee Fenge Li |
| author_facet | Jiandong Hu Mengli Jin Weihong Feng Barbara Nassif-Rausseo Alexandre Reuben Chunhua Ma Gregory Lizee Fenge Li |
| author_sort | Jiandong Hu |
| collection | DOAJ |
| description | Malignant tumors represent a significant threat to human health. Among the various therapeutic strategies available, cancer immunotherapy—encompassing adoptive cell transfer (ACT) and immune checkpoint blockade therapy—has emerged as a particularly promising approach following surgical resection, radiotherapy, chemotherapy, and molecular targeted therapies. This form of treatment elicits substantial antigen-specific immune responses, enhances or restores anti-tumor immunity, thereby facilitating the control and destruction of tumor cells, and yielding durable responses across a range of cancers, which can lead to the eradication of tumor lesions and the prevention of recurrence. Tumor-infiltrating lymphocytes (TILs), a subset of ACT, are characterized by their heterogeneity and are found within tumor tissues, where they play a crucial role in mediating host antigen-specific immune responses against tumors. This review aims to explore recent advancements in the understanding of TILs biology, their prognostic implications, and their predictive value in therapeutic contexts. |
| format | Article |
| id | doaj-art-2211fa542f4342aa874bfab0f94e32ff |
| institution | Kabale University |
| issn | 2076-393X |
| language | English |
| publishDate | 2025-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj-art-2211fa542f4342aa874bfab0f94e32ff2025-08-20T03:47:57ZengMDPI AGVaccines2076-393X2025-05-0113552110.3390/vaccines13050521Clinical and Fundamental Research Progressions on Tumor-Infiltrating Lymphocytes Therapy in CancerJiandong Hu0Mengli Jin1Weihong Feng2Barbara Nassif-Rausseo3Alexandre Reuben4Chunhua Ma5Gregory Lizee6Fenge Li7Core Laboratory, Tianjin Beichen Hospital, Tianjin 300400, ChinaCore Laboratory, Tianjin Beichen Hospital, Tianjin 300400, ChinaDepartment of Oncology, Tianjin Beichen Hospital, Tianjin 300400, ChinaDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USADepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USACancer Diagnosis and Treatment Center, Tianjin Union Medical Cancer Center (The First Affiliated Hospital of Nankai University), Tianjin 300121, ChinaDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USACore Laboratory, Tianjin Beichen Hospital, Tianjin 300400, ChinaMalignant tumors represent a significant threat to human health. Among the various therapeutic strategies available, cancer immunotherapy—encompassing adoptive cell transfer (ACT) and immune checkpoint blockade therapy—has emerged as a particularly promising approach following surgical resection, radiotherapy, chemotherapy, and molecular targeted therapies. This form of treatment elicits substantial antigen-specific immune responses, enhances or restores anti-tumor immunity, thereby facilitating the control and destruction of tumor cells, and yielding durable responses across a range of cancers, which can lead to the eradication of tumor lesions and the prevention of recurrence. Tumor-infiltrating lymphocytes (TILs), a subset of ACT, are characterized by their heterogeneity and are found within tumor tissues, where they play a crucial role in mediating host antigen-specific immune responses against tumors. This review aims to explore recent advancements in the understanding of TILs biology, their prognostic implications, and their predictive value in therapeutic contexts.https://www.mdpi.com/2076-393X/13/5/521tumor-infiltrating lymphocytesmolecular mechanismsmalignant solid tumorclinical responseprognosis |
| spellingShingle | Jiandong Hu Mengli Jin Weihong Feng Barbara Nassif-Rausseo Alexandre Reuben Chunhua Ma Gregory Lizee Fenge Li Clinical and Fundamental Research Progressions on Tumor-Infiltrating Lymphocytes Therapy in Cancer Vaccines tumor-infiltrating lymphocytes molecular mechanisms malignant solid tumor clinical response prognosis |
| title | Clinical and Fundamental Research Progressions on Tumor-Infiltrating Lymphocytes Therapy in Cancer |
| title_full | Clinical and Fundamental Research Progressions on Tumor-Infiltrating Lymphocytes Therapy in Cancer |
| title_fullStr | Clinical and Fundamental Research Progressions on Tumor-Infiltrating Lymphocytes Therapy in Cancer |
| title_full_unstemmed | Clinical and Fundamental Research Progressions on Tumor-Infiltrating Lymphocytes Therapy in Cancer |
| title_short | Clinical and Fundamental Research Progressions on Tumor-Infiltrating Lymphocytes Therapy in Cancer |
| title_sort | clinical and fundamental research progressions on tumor infiltrating lymphocytes therapy in cancer |
| topic | tumor-infiltrating lymphocytes molecular mechanisms malignant solid tumor clinical response prognosis |
| url | https://www.mdpi.com/2076-393X/13/5/521 |
| work_keys_str_mv | AT jiandonghu clinicalandfundamentalresearchprogressionsontumorinfiltratinglymphocytestherapyincancer AT menglijin clinicalandfundamentalresearchprogressionsontumorinfiltratinglymphocytestherapyincancer AT weihongfeng clinicalandfundamentalresearchprogressionsontumorinfiltratinglymphocytestherapyincancer AT barbaranassifrausseo clinicalandfundamentalresearchprogressionsontumorinfiltratinglymphocytestherapyincancer AT alexandrereuben clinicalandfundamentalresearchprogressionsontumorinfiltratinglymphocytestherapyincancer AT chunhuama clinicalandfundamentalresearchprogressionsontumorinfiltratinglymphocytestherapyincancer AT gregorylizee clinicalandfundamentalresearchprogressionsontumorinfiltratinglymphocytestherapyincancer AT fengeli clinicalandfundamentalresearchprogressionsontumorinfiltratinglymphocytestherapyincancer |